Cardax

Cardax Net Debt/Equity

The Net Debt to Equity Ratio of Cardax (CDXI) as of Oct 19, 2026 is -0.47. In the previous year, Net Debt to Equity Ratio was -0.36 — a change of 31.07% (lower).

Net Debt/Equity

-0.47

YoY

31.07%

Last updated:

Net Debt to Equity Ratio of Cardax is 2020 -0.47 . Net Debt to Equity Ratio of Cardax was 2019 -0.36 . It decreases by 31.07% lower compared to the previous year.

The Cardax Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2015
0.09 USD
Jan 1, 2016
0.04 USD
Jan 1, 2017
1.59 USD
Jan 1, 2018
0.07 USD
Jan 1, 2019
-0.36 USD
Jan 1, 2020
-0.47 USD
The Cardax Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.47+31.07%
-0.36-616.83%
0.07-95.67%
1.59+3,803.80%
0.04-52.75%
0.09—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardax Stock analysis

What does Cardax do? Cardax Inc, a development stage biopharmaceutical company based in Honolulu, Hawaii, focuses on developing pharmaceuticals for chronic diseases driven by inflammation. The company has 10 full-time employees and went public via an IPO on January 30, 2012. Cardax is currently developing two pre-clinical pharmaceutical candidates: CDX-101 and CDX-301. CDX-101 is a proprietary astaxanthin prodrug designed to deliver astaxanthin to the bloodstream following oral administration. Astaxanthin is a naturally occurring molecule known for its anti-inflammatory properties, supporting cardiovascular health, metabolic health, liver health, joint health, and longevity. CDX-301 is a pharmaceutical candidate for macular degeneration, utilizing zeaxanthin, which accumulates in the human eye through a retinal receptor to protect against blue light, oxidative damage, and inflammation associated with macular degeneration. The company's headquarters are located in Honolulu, and it operates within the Health Care sector, specifically in the Pharmaceuticals industry. Cardax Inc's website is https://cardaxpharma.com/. The company is seeking to monetize its pre-clinical candidates, CDX-101 and CDX-301, as it advances its development pipeline. No additional details about the company's financials, specific acquisition history, or other product names are provided in the available information. Cardax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cardax stock

Net Debt to Equity Ratio of Cardax is -0.47 in 2020.

Net Debt to Equity Ratio of Cardax changed from -0.36 to -0.47, representing a 31.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Cardax since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Cardax with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cardax

All Key Metrics — Cardax